Healthy volunteers to test new formulation of breast cancer drug HRS-6209
NCT ID NCT07610148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test two different versions of the experimental drug HRS-6209 in 21 healthy Chinese adults. The goal is to see how the body absorbs the old and new capsule forms, and whether a high-fat meal affects absorption. No treatment benefit is expected for participants, as this is purely a pharmacokinetic and safety study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-6209 (an experimental drug for breast cancer)
- What this could lead to
- If successful, this could help develop a better formulation of HRS-6209 for future breast cancer treatment.
- What could go wrong
- This is a very early phase 1 study in healthy people, not patients. It only measures drug levels and safety, not whether the drug works against cancer. Many drugs fail in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fuzhou University Affiliated Provincial Hospital
Fuzhou, Fujian, 350001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?